top of page
Case Studies
Portfolio of non-confidential client projects
Our work often supports ongoing research and long-term partnerships, many of which remain under NDA. The case studies below highlight a few examples we’re able to share publicly. Each project is the result of close collaboration, clear communication, and a deep respect for the science.
Case Studies
Portfolio of non-confidential client projects
Our work often supports ongoing research and long-term partnerships, many of which remain under NDA. The case studies below highlight a few examples we’re able to share publicly—each shaped by close collaboration, clear communication, and a deep respect for the science.
START PROJECT
START PROJECT
1
Sotagliflozin MOA
Part 4 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment features a newly developed therapeutic option in the treatment of heart disease.
Pharmaceutical
Product MOA
2
Atherosclerosis & Glucose Transporters
Part 3 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment explores the development of cardiovascular disease at the physiological level, and explains the connection between energy homeostasis and the progression of atherosclerosis.
Pharmaceutical
Educational MOD
3
Energy Homeostasis & Heart Failure
Part 2 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment highlights the mechanisms and effects of metabolic energy imbalances on the development of heart failure.
Pharmaceutical
Educational MOD
4
Introduction to Cellular Glucose Transporters
Part 1 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment gives an overview of the two major cell glucose transporter families - GLUTs and SGLTs - and explains their individual locations, functions, and potential as therapeutic targets.
Pharmaceutical
Educational
- Page 1
%20Figure%20Atorva%20v4-min_edited.png)
.png)
_VLDL-1.png)
1
Sotagliflozin MOA
Part 4 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment features a newly developed therapeutic option in the treatment of heart disease.
December 2023
Product MOA
2
Atherosclerosis & Glucose Transporters
Part 3 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment explores the development of cardiovascular disease at the physiological level, and explains the connection between energy homeostasis and the progression of atherosclerosis.
September 2023
Educational MOD
3
Energy Homeostasis & Heart Failure
Part 2 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment highlights the mechanisms and effects of metabolic energy imbalances on the development of heart failure.
July 2023
Educational MOD
4
Introduction to Cellular Glucose Transporters
Part 1 of a four part series on cellular glucose transporters, SGLT1/SGLT2 inhibition, and cellular energetics related to cardiovascular disease and heart failure. This installment gives an overview of the two major cell glucose transporter families - GLUTs and SGLTs - and explains their individual locations, functions, and potential as therapeutic targets.
January 2023
Educational
5
Icosapent Ethyl MOA
MOA animation featuring a groundbreaking new drug developed for heart disease. This animation visually explains the multi-faceted molecular mechanisms that underlie the drug's significant CV risk reductions.
March 2023
Product MOA
6
Effects of EPA & DHA Omega-3 Fatty Acids
Scientific animation visualizing the membrane dynamics of omega-3 fatty acids EPA and DHA, as well as their respective effects on lipid peroxidation and cholesterol domain formation.
December 2021
Educational / Pub
- Page 1
bottom of page